GURU.Markets stock price, segment price, and overall market index valuation
The company's share price SAB Biotherapeutics
SAB Biotherapeutics is a unique biotech company producing human antibodies in genetically modified cows. Its stock price is a bet on its platform for developing drugs against infectious and autoimmune diseases.
Share prices of companies in the market segment - Pharma immune
SAB Biotherapeutics is a biotech company that has developed a unique platform for producing human antibodies in cattle to treat infectious and autoimmune diseases. We've categorized it under "Pharma: Immunology." The chart below shows the dynamics of the innovative platform sector.
Broad Market Index - GURU.Markets
SAB Biotherapeutics is developing a unique platform for producing fully human polyclonal antibodies without the need for human donors. Its cutting-edge technology makes it part of the GURU.Markets index. The chart below compares its performance to the market.
Change in the price of a company, segment, and market as a whole per day
SABS - Daily change in the company's share price SAB Biotherapeutics
SAB Biotherapeutics, Inc.'s daily share price fluctuations reflect the high volatility inherent in biotech companies. This metric measures the company's sensitivity to news about clinical trials of its antibody platform.
Daily change in the price of a set of shares in a market segment - Pharma immune
SAB Biotherapeutics, Inc. is a biotech company. This chart highlights the sector's high volatility. Comparison with SABS's performance, with its unique antibody production platform, helps assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
SAB Biotherapeutics has developed a unique platform for producing human antibodies in cows. Shares of this innovative biotech company are reacting to research data. Its story exemplifies the biotech sector's contribution to overall volatility.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization SAB Biotherapeutics
SAB Biotherapeutics' year-to-date performance is the story of its unique platform for producing human antibodies without the use of human donors. Its 12-month market cap depends on progress in its clinical programs. The success of its approach using transgenic cows could revolutionize the way immunoglobulins are produced.
Annual dynamics of market capitalization of the market segment - Pharma immune
SAB Biotherapeutics, Inc. is a biopharmaceutical company developing a new class of antibody-based immunotherapies. Its stock performance is entirely dependent on clinical trial results. The chart reflects the high risks and potential for breakthroughs typical of the biotech sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
SAB Biotherapeutics is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of its unique platform. The company's chart exists in a world of its own, where data releases are the key events.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization SAB Biotherapeutics
SAB Biotherapeutics is developing a unique platform for antibody production. Being in the clinical stage, its monthly growth depends entirely on the progress of its research. News of its drug trial results, as well as government contract awards, are the main drivers.
Monthly dynamics of market capitalization of the market segment - Pharma immune
SAB Biotherapeutics is developing a unique platform for generating human antibodies without the need for human donors. This is a potentially breakthrough technology for the treatment of infectious and autoimmune diseases. The dynamics of the biotech sector demonstrate a general interest in innovation. SAB's story is a bet that its platform will become a new standard in immunotherapy.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
SAB Biotherapeutics, Inc. is a biopharmaceutical company that has developed a unique platform for producing fully human polyclonal antibodies without the need for human donors. The company's future depends on the success of its platform. The broader market chart serves only as a backdrop to understand how its breakthrough scientific technology impacts its valuation.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization SAB Biotherapeutics
SAB Biotherapeutics is developing a unique class of immunotherapy based on antibodies derived from genetically modified cows. The stock's weekly performance is volatile, driven by news of clinical trials and partnerships that could confirm the potential of this unique platform.
Weekly dynamics of market capitalization of the market segment - Pharma immune
SAB Biotherapeutics is developing a unique class of immunotherapy based on antibodies derived from genetically modified cows. The stock's weekly performance is volatile, driven by news of clinical trials and partnerships that could confirm the potential of this unique platform.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
SAB, a biotech company, lives in a world of its own. Its performance is driven by news about its unique technology. A chart comparing the stock to the S&P 500 clearly demonstrates how the stock can rise or fall on company-specific events, completely ignoring the market.
Market capitalization of the company, segment and market as a whole
SABS - Market capitalization of the company SAB Biotherapeutics
SAB Biotherapeutics' market capitalization chart tells the story of a unique technology for producing human antibodies in cows. Its dynamics reflect both the enormous potential of this platform for treating infectious and immune diseases and the challenges facing its commercialization.
SABS - Share of the company's market capitalization SAB Biotherapeutics within the market segment - Pharma immune
SAB Biotherapeutics has developed a unique platform for producing human polyclonal antibodies from the plasma of genetically modified cattle. Its share of its segment's market capitalization reflects the breakthrough nature of this technology. The chart below shows how investors assess its potential for treating various diseases.
Market capitalization of the market segment - Pharma immune
SAB Biotherapeutics has developed a unique platform for producing human antibodies in cows to treat various diseases. The chart below shows the overall market capitalization of the immunopharmaceuticals sector, illustrating innovative, albeit unconventional, approaches to drug discovery.
Market capitalization of all companies included in a broad market index - GURU.Markets
This graph shows a unique way to produce drugs. SAB Biotherapeutics uses genetically modified cows to produce human antibodies against diseases. Their pipeline is a bet on this unusual, yet potentially powerful, biotech platform.
Book value capitalization of the company, segment and market as a whole
SABS - Book value capitalization of the company SAB Biotherapeutics
SAB Biotherapeutics' foundation is its unique platform for producing fully human polyclonal antibodies from the plasma of genetically modified cattle. This represents revolutionary scientific and biological capital. The chart below shows how the company is managing its resources to develop a new class of immunotherapeutic drugs.
SABS - Share of the company's book capitalization SAB Biotherapeutics within the market segment - Pharma immune
SAB Biotherapeutics is a biotechnology company that produces human antibodies in cows. Its unique assets include specialized farms and wastewater treatment facilities. The chart shows the company's share of this unique biomanufacturing infrastructure.
Market segment balance sheet capitalization - Pharma immune
Antibody development, as the BCap_Ges chart for biotech shows, is a capital-intensive niche. SAB Biotherapeutics, with its unique transgenic livestock platform, requires significant investment in biological infrastructure, which sets it apart from others.
Book value of all companies included in the broad market index - GURU.Markets
SAB Biotherapeutics' book value is derived from its unique herds of genetically modified cows that produce human antibodies. It reflects the physical scale of this innovative "biofactory," which is the living material foundation for the creation of a new class of immunotherapy.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - SAB Biotherapeutics
SAB Biotherapeutics has developed a unique platform for producing human antibodies in cows. The value lies in this unique technology. The book value is low. The MvsBCap chart will show how much investors believe this method can be an effective way to quickly develop drugs against new infections.
Market to book capitalization ratio in a market segment - Pharma immune
SAB Biotherapeutics has developed a unique platform for producing human antibodies in cattle. Its value lies in this breakthrough technology. The chart shows how the market perceives its potential in the fight against infectious and immune diseases.
Market to book capitalization ratio for the market as a whole
SAB Biotherapeutics has developed a unique platform for producing human antibodies in cows, enabling rapid development of therapies against new viruses. The company's value lies in this platform. The chart shows how investors evaluate innovative approaches to combating infectious diseases.
Debts of the company, segment and market as a whole
SABS - Company debts SAB Biotherapeutics
SAB Biotherapeutics, a company that has developed a unique platform for producing human antibodies in cows, is using capital to conduct clinical trials of its drugs. This breakthrough technology requires significant investment. This chart shows how the company is funding its research, which could provide a rapid response to emerging infectious threats.
Market segment debts - Pharma immune
SAB Biotherapeutics has developed a unique platform for producing human polyclonal antibodies without the need for human donors. Developing and scaling such a breakthrough biotechnology requires significant investment. The chart below shows how the company is funding its innovative, yet capital-intensive, scientific platform.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio SAB Biotherapeutics
SAB Biotherapeutics is developing a unique platform for generating human antibodies without the need for human donors. This chart shows how the company is funding its revolutionary, yet expensive, research. The high debt is a bet that their technology will be a game-changer in immunotherapy, and any disruption to that process will be critical.
Market segment debt to market segment book capitalization - Pharma immune
SAB Biotherapeutics is developing a unique platform for producing human polyclonal antibodies without the need for human donors. The chart shows the sector's debt burden, helping to assess how the company is financing its revolutionary and capital-intensive technology, which can be used to treat a variety of diseases.
Debt to book value of all companies in the market
SAB Biotherapeutics is developing a unique platform for producing fully human polyclonal antibodies without the need for human donors. For such an innovative company, the overall financial environment, shown in this chart, is vital. Access to capital for commercializing breakthrough biotechnology depends on the health of the market.
P/E of the company, segment and market as a whole
P/E - SAB Biotherapeutics
For SAB Biotherapeutics, a company producing human antibodies without human donors, this chart reflects confidence in its unique platform. High values indicate hopes that its technology will enable the rapid development of powerful drugs to combat infectious diseases such as influenza or COVID-19.
P/E of the market segment - Pharma immune
This chart shows the average P/E ratio for the biotech sector, where SAB Biotherapeutics offers a unique platform. The industry's high valuation reflects a belief in innovation. This metric helps understand the market premium placed on SAB's antibody technology.
P/E of the market as a whole
SAB Biotherapeutics has developed a unique platform for producing human polyclonal antibodies from the plasma of specially bred cows. These antibodies can be used to treat infectious and immune diseases. This chart shows the mood in the biotech industry. It helps us understand the market's confidence in this breakthrough yet complex production platform and its potential for creating new drugs.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company SAB Biotherapeutics
SAB Biotherapeutics has developed a unique platform for producing human antibodies in cows to create immunotherapeutic drugs. This chart illustrates analysts' belief that this innovative technology will enable the rapid development of powerful drugs against infectious and autoimmune diseases.
%20P%2FE%20SAB%20Biotherapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-SAB-Biotherapeutics&v=1772513622173 "Chart of the company's future (projected) P/E SAB Biotherapeutics")
Future (projected) P/E of the market segment - Pharma immune
SAB Biotherapeutics has developed a unique platform for producing fully human polyclonal antibodies without the need for human donors. This chart shows how its future revenue expectations compare to the industry average, reflecting the market's valuation of its breakthrough technology for treating infectious and immune diseases.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-immune&v=1772513622187 "Future (projected) P/E graph of the market segment - Pharma immune")
Future (projected) P/E of the market as a whole
SAB Biotherapeutics has developed a unique platform for producing human antibodies without the need for human donors. This is a breakthrough technology. This chart, reflecting the market's risk appetite, shows how willing investors are to finance such fundamental innovations. Market optimism is critical for attracting capital to platform biotech companies.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513622193 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit SAB Biotherapeutics
SAB Biotherapeutics has developed a unique platform for producing human antibodies in cows to treat various diseases. Profitability is the future goal. This chart shows how much is being invested in this unique technology, which could offer a new way to combat infections and immune disorders.
Profit of companies in the market segment - Pharma immune
SAB Biotherapeutics has developed a unique platform for producing fully human polyclonal antibodies without the need for human donors, using genetically modified cattle. This graph illustrates the overall dynamics in the immunotherapy sector, where innovative production platforms have the potential to radically change approaches to treating infectious and autoimmune diseases.
Overall market profit
SAB Biotherapeutics has developed a unique platform for producing human antibodies without human donors. Commercializing such a breakthrough technology requires massive investment. This graph, reflecting market sentiment, impacts the availability of capital for game-changing pharmaceutical companies.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company SAB Biotherapeutics
SAB Biotherapeutics has developed a unique platform for producing human antibodies in cows, enabling the rapid development of powerful drugs against infectious and autoimmune diseases. This chart summarizes analyst forecasts, which are a bet on the commercialization of this breakthrough biotech platform.
%20profit%20of%20the%20company%20SAB%20Biotherapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-SAB-Biotherapeutics&v=1772513622270 "Graph of future (projected) profit of the company SAB Biotherapeutics")
Future (predicted) profit of companies in the market segment - Pharma immune
SAB Biotherapeutics has developed a unique platform for producing fully human polyclonal antibodies without the need for human donors. The antibodies are produced by transgenic cows and can be used to treat infectious and autoimmune diseases. This chart shows profitability projections for the biotech sector, reflecting the potential of such breakthrough production platforms.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-immune&v=1772513622275 "Graph of future (predicted) profits of companies in a market segment - Pharma immune")
Future (predicted) profit of the market as a whole
SAB Biotherapeutics has developed a unique platform for producing human antibodies without the need for human donors. Commercializing this technology requires significant investment. This graph, reflecting market sentiment, influences investor willingness to fund breakthrough but unproven biotech platforms.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513622288 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - SAB Biotherapeutics
SAB Biotherapeutics has developed a unique platform for producing human antibodies without human donors. This chart shows the market valuation of this breakthrough technology. The high valuation reflects the potential of its platform for the rapid development of drugs for various diseases.
P/S market segment - Pharma immune
SAB Biotherapeutics, Inc. is developing a new class of immunotherapeutic drugs based on human polyclonal antibodies derived from genetically modified cows. This chart shows the average revenue estimate in the biotech sector. It allows us to estimate the premium investors are willing to pay for SAB's unique and potentially powerful platform.
P/S of the market as a whole
SAB Biotherapeutics has developed a unique platform for creating fully human polyclonal antibodies without the need for human donors, using specially bred cows. Their technology can be used to fight infections and cancer. This chart provides a general revenue metric against which to judge how highly investors value breakthrough biotech platforms.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company SAB Biotherapeutics
SAB Biotherapeutics has developed a unique platform for producing human antibodies in genetically modified cows, enabling the rapid development of drugs against infectious diseases. This graph reflects investor expectations for this technology, based on its potential for rapid response to emerging pandemics.
%20P%2FS%20SAB%20Biotherapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-SAB-Biotherapeutics&v=1772513622513 "The graph of the company's future (projected) P/S SAB Biotherapeutics")
Future (projected) P/S of the market segment - Pharma immune
SAB Biotherapeutics has developed a unique platform for producing fully human polyclonal antibodies without the need for human donors. This could be used to treat infectious and autoimmune diseases. This chart shows how the market is valuing its breakthrough biotech platform.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20immune&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-immune&v=1772513622568 "Future (projected) P/S market segment graph - Pharma immune")
Future (projected) P/S of the market as a whole
SAB Biotherapeutics has developed a unique platform for producing human polyclonal antibodies using the plasma of genetically modified cows. This milestone, reflecting investor willingness to fund breakthrough scientific platforms, is important for SAB. Market optimism is essential for scaling this innovative technology, which can rapidly develop treatments for emerging threats.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513622594 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales SAB Biotherapeutics
SAB Biotherapeutics has developed a unique platform for producing fully human polyclonal antibodies without the need for human donors. This chart reflects revenue from government contracts and partnerships. It shows the financial support for this innovative technology, which can be used to combat infectious diseases and cancer.
Sales of companies in the market segment - Pharma immune
SAB Biotherapeutics, Inc. has developed a unique platform for producing human polyclonal antibodies without the need for human donors. Its business is segmented into various therapeutic programs for the treatment of infectious and autoimmune diseases. This chart shows the financial flows associated with one of its key candidates.
Overall market sales
SAB Biotherapeutics has developed a unique platform for producing human antibodies in cows. These antibodies can be used to treat infectious and autoimmune diseases. This breakthrough technology could enable the rapid development of powerful drugs. The company's success depends on clinical data and the implementation of this new production platform.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company SAB Biotherapeutics
SAB Biotherapeutics has developed a unique platform for producing fully human polyclonal antibodies without the need for human donors. Future sales projections are a bet that its technology will rapidly produce powerful drugs for the treatment and prevention of infectious and immune diseases.
%20sales%20of%20the%20company%20SAB%20Biotherapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-SAB-Biotherapeutics&v=1772513622790 "Schedule of future (projected) sales of the company SAB Biotherapeutics")
Future (projected) sales of companies in the market segment - Pharma immune
SAB Biotherapeutics has developed a unique platform for producing human polyclonal antibodies without the need for human donors. This graph illustrates expectations for the entire immunotherapy sector. It helps assess the potential analysts predict for new antibody platforms for treating infectious and autoimmune diseases.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-immune&v=1772513622795 "Schedule of future (projected) sales of companies in the market segment - Pharma immune")
Future (projected) sales of the market as a whole
SAB Biotherapeutics has developed a unique platform for producing human antibodies without human donors. Its future depends on investments and partnerships. This chart of overall sales forecasts reflects market sentiment, which influences the willingness of investors and pharma giants to invest in breakthrough technologies.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513622818 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality SAB Biotherapeutics
SAB Biotherapeutics, Inc. has developed a unique platform for producing fully human polyclonal antibodies without the need for human donors. This chart depicts the company's financial trajectory, comparing revenue from partnerships and government contracts with the costs of scaling this breakthrough technology.
Market segment marginality - Pharma immune
SAB Biotherapeutics has developed a unique platform for producing human antibodies without the need for human donors. The effectiveness of their technology could revolutionize the treatment of infectious and immune diseases. The graph shows their operating costs for commercialization of this innovative platform.
Market marginality as a whole
SAB Biotherapeutics has developed a unique platform for producing fully human polyclonal antibodies without the need for human donors. This can be used to treat a variety of diseases. This graph illustrates the profitability of traditional pharmaceuticals, but for SABS, breakthrough technology capable of rapidly creating potent antibodies is key to value creation.
Employees in the company, segment and market as a whole
Number of employees in the company SAB Biotherapeutics
SAB Biotherapeutics has developed a unique platform for producing human antibodies in cows. This graph shows the team, which combines biologists and animal husbandry specialists. The size of the team reflects the scale of their unique and sophisticated manufacturing and research facilities.
Share of the company's employees SAB Biotherapeutics within the market segment - Pharma immune
SAB Biotherapeutics has developed a unique platform for producing human antibodies in cows, enabling rapid development of therapies against new viruses. This breakthrough approach requires a unique team. This statistic reflects the company's extensive expertise in the cutting-edge field of immunology.
Number of employees in the market segment - Pharma immune
SAB Biotherapeutics has developed a unique platform for producing human polyclonal antibodies based on genetically modified livestock. This chart shows employment in the immunology sector. The growing number of scientists in this field indicates the search for new ways to combat viruses and immune diseases, where SAB's technology may offer a unique solution.
Number of employees in the market as a whole
SAB Biotherapeutics has developed a unique platform for producing antibodies without human donors. Its growth depends on partnerships with major pharmaceutical companies. This chart shows overall occupancy, but for SAB, proving the benefits of its technology to become an industry standard is more important.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company SAB Biotherapeutics (SABS)
SAB Biotherapeutics, Inc. has developed a platform for producing human polyclonal antibodies without the need for human donors. This is a unique technology. The enormous market capitalization per employee in this chart reflects investors' faith in the revolutionary potential of this platform, created by a small but elite team of scientists.
%20of%20the%20company%20SAB%20Biotherapeutics%20(SABS)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-SAB-Biotherapeutics-SABS&v=1772513623105 "Chart of market capitalization per employee (in thousands of dollars) of the company SAB Biotherapeutics (SABS)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma immune
SAB Biotherapeutics, Inc. is developing a unique platform for producing fully human polyclonal antibodies without the need for human donors. This metric reflects the market's appreciation of their breakthrough technology and measures investors' faith in their ability to create a new class of drugs.
%20by%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-immune&v=1772513623127 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma immune")
Market capitalization per employee (in thousands of dollars) for the overall market
SAB Biotherapeutics has developed a unique platform for producing fully human polyclonal antibodies without the need for human donors. The chart demonstrates the high market valuation of this potentially breakthrough biotech platform.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513623159 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company SAB Biotherapeutics (SABS)
SAB Biotherapeutics (SABS) is a unique biotech company. They use genetically engineered cattle to produce human polyclonal antibodies to treat infectious and autoimmune diseases. It's an antibody "farm." This negative graph shows how much capital is "burned" per scientist and technician to prove the viability of this unique R&D platform.
%20Chart%20SAB%20Biotherapeutics%20(SABS)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-SAB-Biotherapeutics-SABS&v=1772513623175 "Company Profit Per Employee (in thousands of dollars) Chart SAB Biotherapeutics (SABS)")
Profit per employee (in thousands of dollars) in the market segment - Pharma immune
SAB Biotherapeutics has developed a unique platform for producing fully human polyclonal antibodies without the need for human donors. This breakthrough technology requires an elite scientific team. This graph shows the value they are creating, which serves as an indicator of the potential of their platform within the broader biopharmaceutical industry.
%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-immune&v=1772513623193 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma immune")
Profit per employee (in thousands of dollars) for the market as a whole
SAB Biotherapeutics (SABS) is a biotech company producing human antibodies in cows (the DiversitAb platform). This is an R&D platform. Negative profit per employee is the norm. The graph shows the "cost" of the team of scientists working on this unique technological platform.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513623196 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee SAB Biotherapeutics (SABS)
SAB Biotherapeutics has developed a unique platform for producing human antibodies in cattle. This graph shows the potential of this technology. Revenue per employee growth will depend on contract wins for the development of treatments for various diseases.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-SAB-Biotherapeutics-SABS&v=1772513623207 "Sales chart per company employee SAB Biotherapeutics (SABS)")
Sales per employee in the market segment - Pharma immune
SAB Biotherapeutics uses a unique platform (specially bred cattle) to produce human antibodies without human donors. This chart compares revenue per employee to the industry average, demonstrating how productive this innovative yet complex biotech model is compared to traditional R&D.
Sales per employee for the market as a whole
SAB Biotherapeutics (SABS) is a biotech company with a unique platform: they use genetically engineered cows to produce human antibodies to treat diseases. This is an R&D platform. The company has no commercial revenue. This graph will reflect $0 or revenue from government contracts/partnerships.
Short shares by company, segment and market as a whole
Shares shorted by company SAB Biotherapeutics (SABS)
SAB Biotherapeutics (SABS) is a unique company. They use genetically modified cows to produce human antibodies to treat diseases. This is a very complex and expensive biotechnology. This chart shows the number of investors who consider this platform too exotic and unviable.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-SAB-Biotherapeutics-SABS&v=1772513623237 "Short Shares Chart for the Company SAB Biotherapeutics (SABS)")
Shares shorted by market segment - Pharma immune
SAB Biotherapeutics (SABS) is a unique company. They use genetically modified cows to produce human antibodies on an industrial scale to treat diseases. This chart shows the bets against the immunotherapy sector, reflecting the extreme skepticism of investors regarding this unusual and complex production platform.
Shares shorted by the overall market
SAB Biotherapeutics uses a unique platform (plasma from genetically modified cows) to create antibodies. This is a pioneering but complex biotech. This chart illustrates the overall market pessimism. When fear mounts, investors avoid complex scientific stories. They are selling off SABS shares because they are unsure of the economic viability of such a complex production platform.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator SAB Biotherapeutics (SABS)
SAB Biotherapeutics (SABS) is developing a platform for creating polyclonal antibodies to treat complex diseases. This unique technology is attracting attention, but it carries risks. This indicator helps assess the strength of market momentum. It shows when shares enter overbought (above 70) or oversold (below 30) territory, reflecting peaks in investor optimism or pessimism.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-SAB-Biotherapeutics-SABS&v=1772513623286 "RSI 14 indicator chart for the company's stock SAB Biotherapeutics (SABS)")
RSI 14 Market Segment - Pharma immune
SAB Biotherapeutics (SABS) has a unique platform: they use genetically modified cattle as "bioreactors" to produce human polyclonal antibodies to treat diseases. This chart tracks overall sentiment in the Pharma/Immunology sector. It helps investors understand whether the entire sector is overhyped or oversold, providing a backdrop for SABS's valuation.
RSI 14 for the overall market
SAB Biotherapeutics (SABS) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast SABS (SAB Biotherapeutics)
SAB Biotherapeutics (SABS) is a unique biopharmaceutical company. It produces human-derived polyclonal antibodies to treat immune diseases using genetically engineered livestock (rather than donors). This chart shows the speculative average price target from analysts based on their belief in this R&D platform.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-SABS-SAB-Biotherapeutics&v=1772513623329 "A chart showing analyst consensus forecasts for the expected stock price. SABS (SAB Biotherapeutics)")
The difference between the consensus estimate and the actual stock price SABS (SAB Biotherapeutics)
SAB Biotherapeutics is a unique biotechnology company. The company produces "human" antibodies... in cows. Their platform (DiversitAb) enables the rapid development of antiviral therapies. This chart shows the difference between the market valuation and the consensus forecast. It reveals whether experts believe in this unusual yet powerful R&D platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-SABS-SAB-Biotherapeutics&v=1772513623337 "A chart showing the difference between the consensus forecast and the actual stock price. SABS (SAB Biotherapeutics)")
Analyst consensus forecast for stock prices by market segment - Pharma immune
SAB Biotherapeutics (SABS) is a biotech company with a unique platform: it uses genetically modified cattle to produce "fully human" polyclonal antibodies. This chart shows general expectations for the immunopharma sector, reflecting experts' confidence in this "animal-based" R&D platform.
Analysts' consensus forecast for the overall market share price
SAB Biotherapeutics (SABS) is a company with a unique "factory." They use genetically modified cows to produce human antibodies on an industrial scale. This chart shows the overall risk appetite, reflecting the willingness of investors to fund breakthrough, but extremely risky, scientific R&D platforms.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index SAB Biotherapeutics
SAB Biotherapeutics is a true antibody factory. They have a unique R&D platform: they use genetically modified cows to produce human polyclonal antibodies (drugs) to combat complex viruses and immune diseases. This graph is a clear indicator of faith in their futuristic science. It reflects their progress in R&D and their ability to scale this complex bio-farm.
AKIMA Market Segment Index - Pharma immune
SAB Biotherapeutics (SABS) is a unique biopharmaceutical company. They produce fully human polyclonal antibodies (without human donors) using genetically modified cattle as a biofactory. The chart shows the segment average, helping investors assess how this breakthrough platform compares to the sector average.
The AKIM Index for the overall market
SAB Biotherapeutics is a biotech company that uses genetically modified cows to produce fully human polyclonal antibodies (immunotherapy). This chart, which reflects the market average, provides a macro backdrop. It helps assess how this unique "DiversitAb" platform compares to overall economic trends.
